Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.24
BAX's Cash to Debt is ranked higher than
51% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. BAX: 0.24 )
BAX' s 10-Year Cash to Debt Range
Min: 0.09   Max: 0.92
Current: 0.24

0.09
0.92
Equity to Asset 0.34
BAX's Equity to Asset is ranked higher than
52% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BAX: 0.34 )
BAX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.47
Current: 0.34

0.22
0.47
Interest Coverage 17.21
BAX's Interest Coverage is ranked higher than
67% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. BAX: 17.21 )
BAX' s 10-Year Interest Coverage Range
Min: 3.8   Max: 32.02
Current: 17.21

3.8
32.02
F-Score: 5
Z-Score: 3.28
M-Score: -2.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.48
BAX's Operating margin (%) is ranked higher than
89% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. BAX: 17.48 )
BAX' s 10-Year Operating margin (%) Range
Min: 9.41   Max: 22.9
Current: 17.48

9.41
22.9
Net-margin (%) 13.19
BAX's Net-margin (%) is ranked higher than
86% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. BAX: 13.19 )
BAX' s 10-Year Net-margin (%) Range
Min: 4.08   Max: 17.55
Current: 13.19

4.08
17.55
ROE (%) 23.77
BAX's ROE (%) is ranked higher than
95% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. BAX: 23.77 )
BAX' s 10-Year ROE (%) Range
Min: 10.47   Max: 33.77
Current: 23.77

10.47
33.77
ROA (%) 7.78
BAX's ROA (%) is ranked higher than
83% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BAX: 7.78 )
BAX' s 10-Year ROA (%) Range
Min: 2.74   Max: 13.07
Current: 7.78

2.74
13.07
ROC (Joel Greenblatt) (%) 26.06
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. BAX: 26.06 )
BAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 16.72   Max: 42.95
Current: 26.06

16.72
42.95
Revenue Growth (%) 8.70
BAX's Revenue Growth (%) is ranked higher than
79% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BAX: 8.70 )
BAX' s 10-Year Revenue Growth (%) Range
Min: -3.5   Max: 17.3
Current: 8.7

-3.5
17.3
EBITDA Growth (%) 12.30
BAX's EBITDA Growth (%) is ranked higher than
82% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. BAX: 12.30 )
BAX' s 10-Year EBITDA Growth (%) Range
Min: -12.2   Max: 33
Current: 12.3

-12.2
33
EPS Growth (%) 15.30
BAX's EPS Growth (%) is ranked higher than
83% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. BAX: 15.30 )
BAX' s 10-Year EPS Growth (%) Range
Min: -17.1   Max: 61.5
Current: 15.3

-17.1
61.5
» BAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BAX Guru Trades in Q3 2013

Ray Dalio 251,063 sh (+339.84%)
Jeremy Grantham 2,709,258 sh (+27.06%)
Bill Nygren 1,523,000 sh (+21.55%)
Jean-Marie Eveillard 1,350,086 sh (+17.98%)
Jim Simons 1,813,000 sh (+16.5%)
Manning & Napier Advisors, Inc 256,267 sh (+5.17%)
Robert Olstein 62,000 sh (+3.33%)
John Buckingham 98,155 sh (+2.61%)
John Hussman 257,450 sh (+0.98%)
Signature Select Canadian Fund 428,400 sh (+0.92%)
Caxton Associates 400,000 sh (unchged)
Chris Davis 5,495 sh (unchged)
Murray Stahl 4,272 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Jeff Auxier 22,981 sh (unchged)
John Rogers 49,271 sh (unchged)
Vanguard Health Care Fund 3,179,300 sh (unchged)
Tweedy Browne 2,603,888 sh (-0.12%)
Diamond Hill Capital 1,707,999 sh (-0.15%)
Bill Frels 1,754,137 sh (-0.81%)
Mario Gabelli 240,900 sh (-1.65%)
Scott Black 18,079 sh (-1.97%)
Dodge & Cox 3,382 sh (-5.58%)
Pioneer Investments 538,124 sh (-16.49%)
James Barrow 2,076,268 sh (-41.52%)
Steven Cohen 90,581 sh (-78.99%)
Paul Tudor Jones 12,900 sh (-96.63%)
» More
Q4 2013

BAX Guru Trades in Q4 2013

Scott Black 158,392 sh (+776.11%)
John Rogers 61,251 sh (+24.31%)
Robert Olstein 77,000 sh (+24.19%)
Bill Frels 2,155,658 sh (+22.89%)
Jeff Auxier 25,981 sh (+13.05%)
Jeremy Grantham 2,919,918 sh (+7.78%)
John Buckingham 98,705 sh (+0.56%)
Dodge & Cox 3,382 sh (unchged)
Murray Stahl 4,272 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Chris Davis 5,495 sh (unchged)
Bill Nygren 1,523,000 sh (unchged)
Pioneer Investments Sold Out
James Barrow Sold Out
Steven Cohen Sold Out
Tweedy Browne 2,601,953 sh (-0.07%)
Diamond Hill Capital 1,654,045 sh (-3.16%)
Mario Gabelli 227,850 sh (-5.42%)
Manning & Napier Advisors, Inc 228,450 sh (-10.85%)
Vanguard Health Care Fund 2,410,000 sh (-24.2%)
Ray Dalio 188,663 sh (-24.85%)
Jim Simons 951,600 sh (-47.51%)
Paul Tudor Jones 5,600 sh (-56.59%)
John Hussman 107,450 sh (-58.26%)
Jean-Marie Eveillard 7,600 sh (-99.44%)
» More
Q1 2014

BAX Guru Trades in Q1 2014

David Dreman 2,453 sh (New)
Steven Cohen 256,874 sh (New)
Charles Brandes 204,560 sh (New)
Jeremy Grantham 3,521,356 sh (+20.6%)
Paul Tudor Jones 6,400 sh (+14.29%)
Scott Black 179,629 sh (+13.41%)
Bill Frels 2,342,265 sh (+8.66%)
Diamond Hill Capital 1,769,316 sh (+6.97%)
Bill Nygren 1,623,000 sh (+6.57%)
John Buckingham 100,126 sh (+1.44%)
Dodge & Cox 3,404 sh (+0.65%)
Murray Stahl 4,272 sh (unchged)
Tweedy Browne 2,601,848 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Rogers 61,251 sh (unchged)
Jeff Auxier 25,981 sh (unchged)
Chris Davis Sold Out
Mario Gabelli 225,500 sh (-1.03%)
Manning & Napier Advisors, Inc 216,402 sh (-5.27%)
Robert Olstein 68,000 sh (-11.69%)
Jim Simons 812,400 sh (-14.63%)
Ray Dalio 62,263 sh (-67%)
Signature Select Canadian Fund 103,600 sh (-75.82%)
Vanguard Health Care Fund 531,100 sh (-77.96%)
Jean-Marie Eveillard 1,100 sh (-85.53%)
John Hussman 7,450 sh (-93.07%)
» More
Q2 2014

BAX Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 218,691 sh (+1.06%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-03-31 Reduce -93.07%0.49%$66.49 - $72.85 $ 76.3411%7450
Vanguard Health Care Fund 2014-03-31 Reduce -77.96%0.41%$66.49 - $72.85 $ 76.3411%531100
Charles Brandes 2014-03-31 New Buy0.19%$66.49 - $72.85 $ 76.3411%204560
Scott Black 2014-03-31 Add 13.41%0.17%$66.49 - $72.85 $ 76.3411%179629
Ray Dalio 2014-03-31 Reduce -67%0.07%$66.49 - $72.85 $ 76.3411%62263
David Dreman 2014-03-31 New Buy0.01%$66.49 - $72.85 $ 76.3411%2453
Jean-Marie Eveillard 2014-03-31 Reduce -85.53%$66.49 - $72.85 $ 76.3411%1100
Scott Black 2013-12-31 Add 776.11%1.06%$63.89 - $69.47 $ 76.3414%158392
John Hussman 2013-12-31 Reduce -58.26%0.54%$63.89 - $69.47 $ 76.3414%107450
Jean-Marie Eveillard 2013-12-31 Reduce -99.44%0.26%$63.89 - $69.47 $ 76.3414%7600
James Barrow 2013-12-31 Sold Out 0.22%$63.89 - $69.47 $ 76.3414%0
Vanguard Health Care Fund 2013-12-31 Reduce -24.2%0.17%$63.89 - $69.47 $ 76.3414%2410000
Ray Dalio 2013-12-31 Reduce -24.85%0.03%$63.89 - $69.47 $ 76.3414%188663
James Barrow 2013-09-30 Reduce -41.52%0.17%$66.35 - $74.43 $ 76.347%2076268
Ray Dalio 2013-09-30 Add 339.84%0.11%$66.35 - $74.43 $ 76.347%251063
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc - Jul 25, 2014

We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Baxter International - Jan 15, 2014

Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market. 

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Baxter International - Oct 24, 2012

Medical supply manufacturer Baxter International, Inc. (BAX) reported solid second quarter results, which included strong volume and pricing in its antibody therapy. In addition, the company raised its dividend 34% and added $2 billion to its share repurchase capacity. Baxter is planning to add more capacity to break blood plasma into its component parts, which suggests the company is optimistic about future demand.

From Diamond Hill Capital's third quarter Select Fund Commentary.


Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc
We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position. Read more...
Diamond Hill Capital Comments on Baxter International
Baxter International, Inc. (BAX), a medical supply manufacturer, declined during the quarter due to concerns that it could lose more market share than expected in the hemophilia market.  Read more...
'High Five' from Superinvestor James Barrow - Reductions in Second Quarter
Guru James Barrow’s Vanguard Select Value Fund outperformed the S&P 500 eight out of the last 10 years with a cumulative gain of 104%, while the S&P 500 gained 34.9%. Barrow has averaged returns of 14.97% over 12 months, according to the GuruFocus Score Board of Gurus. The recent portfolio update of Guru James Barrow, executive director of Barrow, Hanley, Mewhinney & Strauss shows 20 new stocks. Barrow lists 171 stocks with a total value of $5.95 billion and a quarter-over-quarter turnover of 9%. The firm currently manages more than $70 billion in assets. His top three sectors are financial services at 23.9%, health care at 16.8% and technology at 14.8%. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 21.20
BAX's P/E(ttm) is ranked higher than
87% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 35.10 vs. BAX: 21.20 )
BAX' s 10-Year P/E(ttm) Range
Min: 12.15   Max: 57.43
Current: 21.2

12.15
57.43
P/B 4.80
BAX's P/B is ranked higher than
61% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. BAX: 4.80 )
BAX' s 10-Year P/B Range
Min: 3.78   Max: 6.39
Current: 4.8

3.78
6.39
P/S 2.70
BAX's P/S is ranked higher than
73% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. BAX: 2.70 )
BAX' s 10-Year P/S Range
Min: 1.82   Max: 3.88
Current: 2.7

1.82
3.88
PFCF 24.70
BAX's PFCF is ranked higher than
87% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 83.00 vs. BAX: 24.70 )
BAX' s 10-Year PFCF Range
Min: 12.81   Max: 29.77
Current: 24.7

12.81
29.77
EV-to-EBIT 17.51
BAX's EV-to-EBIT is ranked higher than
83% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. BAX: 17.51 )
BAX' s 10-Year EV-to-EBIT Range
Min: 10   Max: 28.8
Current: 17.51

10
28.8
PEG 3.20
BAX's PEG is ranked higher than
86% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. BAX: 3.20 )
BAX' s 10-Year PEG Range
Min: 0.65   Max: 409.33
Current: 3.2

0.65
409.33
Shiller P/E 20.90
BAX's Shiller P/E is ranked higher than
95% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 20.90 )
BAX' s 10-Year Shiller P/E Range
Min: 14.63   Max: 36.78
Current: 20.9

14.63
36.78
Current Ratio 1.66
BAX's Current Ratio is ranked higher than
58% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. BAX: 1.66 )
BAX' s 10-Year Current Ratio Range
Min: 1.08   Max: 2.7
Current: 1.66

1.08
2.7
Quick Ratio 1.00
BAX's Quick Ratio is ranked higher than
55% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. BAX: 1.00 )
BAX' s 10-Year Quick Ratio Range
Min: 0.74   Max: 2.02
Current: 1

0.74
2.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.60
BAX's Dividend Yield is ranked higher than
84% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. BAX: 2.60 )
BAX' s 10-Year Dividend Yield Range
Min: 1.13   Max: 2.95
Current: 2.6

1.13
2.95
Dividend Payout 0.53
BAX's Dividend Payout is ranked higher than
90% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 0.53 )
BAX' s 10-Year Dividend Payout Range
Min: 0.26   Max: 3.4
Current: 0.53

0.26
3.4
Dividend growth (3y) 17.60
BAX's Dividend growth (3y) is ranked higher than
90% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. BAX: 17.60 )
BAX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 22.5
Current: 17.6

0
22.5
Yield on cost (5-Year) 5.39
BAX's Yield on cost (5-Year) is ranked higher than
92% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. BAX: 5.39 )
BAX' s 10-Year Yield on cost (5-Year) Range
Min: 2.34   Max: 6.12
Current: 5.39

2.34
6.12
Share Buyback Rate 2.60
BAX's Share Buyback Rate is ranked higher than
94% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BAX: 2.60 )
BAX' s 10-Year Share Buyback Rate Range
Min: 7.7   Max: -10.6
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.00
BAX's Price/Tangible Book is ranked higher than
59% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.06 vs. BAX: 19.00 )
BAX' s 10-Year Price/Tangible Book Range
Min: 3.91   Max: 27.72
Current: 19

3.91
27.72
Price/DCF (Projected) 1.50
BAX's Price/DCF (Projected) is ranked higher than
87% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.03 vs. BAX: 1.50 )
BAX' s 10-Year Price/DCF (Projected) Range
Min: 1.02   Max: 4.96
Current: 1.5

1.02
4.96
Price/Median PS Value 1.10
BAX's Price/Median PS Value is ranked higher than
75% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. BAX: 1.10 )
BAX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.55
Current: 1.1

0.3
2.55
Price/Peter Lynch Fair Value 3.10
BAX's Price/Peter Lynch Fair Value is ranked higher than
88% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BAX: 3.10 )
BAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.73   Max: 8.11
Current: 3.1

0.73
8.11
Price/Graham Number 4.20
BAX's Price/Graham Number is ranked higher than
74% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.73 vs. BAX: 4.20 )
BAX' s 10-Year Price/Graham Number Range
Min: 1.65   Max: 6.68
Current: 4.2

1.65
6.68
Earnings Yield (Greenblatt) 5.60
BAX's Earnings Yield (Greenblatt) is ranked higher than
74% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. BAX: 5.60 )
BAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 10
Current: 5.6

3.5
10
Forward Rate of Return (Yacktman) 10.05
BAX's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. BAX: 10.05 )
BAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 25.8
Current: 10.05

0.1
25.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, COV, TMO, COO, ISRG » details
Traded in other countries:BAX.Switzerland, BTL.Germany, 0QK8.country
Baxter International Inc., is a Delaware corporation incorporated in 1931. It is a diversified healthcare company. Through its subsidiaries, it develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy, and also distributes products for hemodialysis (HD), which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. BioScience continues to face competitors from pharmaceutical, biotechnology and other companies. Medical Products face competition from medical device manufacturers and pharmaceutical companies. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.
» More Articles for BAX

Headlines

Articles On GuruFocus.com
Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
Why I Bought Baxter International Jun 19 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
Two Stocks On My Watch List For June 2014 May 29 2014 
Companies That Are Raising Dividends May 16 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
4 Top Stocks in the Medical Device Sector Apr 11 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Diamond Hill Capital Comments on Baxter International Jan 15 2014 
Diamond Hill Capital Large Cap Fund Q3 Commentary Jan 15 2014 

More From Other Websites
Baxter Announces Divestiture of Commercial Vaccines Business to Pfizer Jul 30 2014
Pfizer to buy Baxter’s vaccines for $635 million Jul 30 2014
[$$] Pfizer To Buy Baxter's Vaccines Jul 30 2014
8:03 am Baxter announces divestiture of commercial vaccines business to Pfizer (Jul 30 2014
Baxter Announces Divestiture of Commercial Vaccines Business to Pfizer Jul 30 2014
BAX, WLP And COV, 3 Health Services Stocks Pushing The Industry Lower Jul 25 2014
New Lifetime High Today: Baxter International (BAX) Jul 23 2014
Baxter Declares Quarterly Dividend Jul 22 2014
Baxter Declares Quarterly Dividend Jul 22 2014
Why Baxter Is A Fine Dividend Growth Idea Jul 18 2014
Gambro acquisition boosts Baxter's sales Jul 17 2014
UPDATE 1-Medical products boost Baxter's sales Jul 17 2014
Baxter International Tops Earnings Ests but Shrinks Guidance Jul 17 2014
Baxter Q2 Earnings Beat Estimates, But Guidance Soft Jul 17 2014
Baxter Exceeds Expectations in Second Quarter with Strong Growth across Global Franchises Jul 17 2014
Baxter says 'feels good' about guidance Jul 17 2014
Baxter International Inc Earnings Call scheduled for 8:30 am ET today Jul 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Sww
ReplySww - 4 weeks ago
Bax medical devices revenue ~9b, bio science ~7b
using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

72 * (1 + 16/39) = 99

72 is current stock price, with an upside of around 35%

so my guess is BAX may be able to sell for around 90 after spin-off.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide